Intra-cellular Therapies, Inc.

This study tested whether a medication called ITI-007 could help control symptoms in people experiencing a schizophrenia flare-up. Researchers compared the drug against a placebo in 450 adults with schizophrenia over 28 days. They measured changes in symptoms like hallucinations,…

This study aimed to check the long-term safety of adding a new medication called lumateperone to standard antidepressant therapy for people with major depression. Over 800 patients who had already completed a prior study took lumateperone daily for about six months while continui…

This large Phase 3 study tested whether a new medication called ITI-007 could help control symptoms in people experiencing a sudden worsening of schizophrenia. For 6 weeks, 696 adult patients received either ITI-007, an existing antipsychotic medication, or a placebo pill, with n…

This large, completed study tested whether a medication called ITI-007 (lumateperone) could safely help reduce depressive symptoms in adults with bipolar disorder. Over 550 participants with bipolar I or II disorder who were experiencing a major depressive episode were randomly a…

This study tested whether a new medication called ITI-007 could reduce symptoms in people with schizophrenia who were experiencing a sudden worsening of their psychosis. 335 participants were randomly assigned to receive either one of two doses of ITI-007, a placebo (inactive pil…

This early study aimed to understand how a new drug called ITI-333 interacts with the brain. Researchers gave single doses to 12 healthy volunteers and used brain scans to see how much of the drug attached to a specific brain target. The main goals were to check the drug's safety…

This was an early, small study to check the safety of a new drug called ITI-333 and see how the body processes it. It involved 32 healthy volunteers who took the drug or a placebo (a dummy pill) daily for two weeks. The main goal was to find out if the drug was safe and well-tole…

This early-stage study aimed to understand how a drug called lumateperone is processed by the body and to check its safety in teenagers with schizophrenia or schizoaffective disorder. It involved 26 participants aged 13 to 17 who were stable in their condition. The main goal was …